Esophageal Cancer Market Revenue to Attain USD 31.44 Bn by 2033

07 Jul 2025

Share :

Table of Content

1. Esophageal Cancer Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Outlook 4. Regional Insights 5. Esophageal Cancer Market Coverage 6. Esophageal Cancer Market Key Players

Esophageal Cancer Market Revenue and Trends 2025 to 2033

The global esophageal cancer market revenue was valued at USD 16.65 billion in 2025 and is expected to attain around USD 31.44 billion by 2033, growing at a CAGR of 8.27% during forecast period. The market is attributed to the increasing number of cases of esophageal cancer, advancements in diagnostic technology, and the development of targeted therapies.

Market Overview

The esophageal cancer market is poised for significant growth, primarily due to the increasing global incidence of esophageal cancer, especially within older populations and people with high tobacco and alcohol consumption levels. Increased knowledge and awareness of esophageal cancer and advancements in endoscopic technology led to early diagnosis, boosting the demand for effective therapies. The emergence of targeted therapies and immunotherapies is changing treatment approaches and is contributing to improved survival rates with fewer adverse effects. The market is also benefitting from an increased pipeline of new drugs. Rising government investments in oncology research create immense opportunities in the market.

Segment Outlook

• By cancer type, the squamous cell carcinoma segment held the largest revenue share of the market in 2024. With its global prevalence, there is a high demand for effective therapeutics to reduce the burden and mortality rates associated with it.
• By diagnosis, the endoscopy segment led the market with the biggest share in 2024. Using endoscopy as a treatment modality offers relevant visuals and biopsy confirmation, clinically establishing it as the gold standard for acute diagnosis.
• By treatment, the therapy type segment continues to dominate the market. This is mainly due to the increased demand for targeted therapies to better manage cancer. The high demand for chemotherapy and the rising development of novel immunotherapies are likely to ensure the growth of the segment.
• By stage the stage II segment dominated the market in 2024 due to the increased number of cases of stage II esophageal cancer. Advances in diagnostic technologies further bolstered segmental growth.
• By route of administration, the intravenous (IV) segment held a major revenue share of the market in 2024 due to the increased demand for targeted therapies to better manage symptoms. Chemotherapies and immunotherapies are often delivered through IV. The rapid onset of action of IV enhances patient outcomes by quickly managing systems.
• By end-user, the hospitals segment led the market in 2024. There is an abrupt increase in the patient pool in hospitals due to the availability of advanced diagnostics and a multidisciplinary oncology team. Favorable reimbursement policies for hospital treatments also support segmental growth.
• By distribution channel, the hospital pharmacies segment held the biggest share of the market in 2024. The easy accessibility to these pharmacies is increasing sales. Differentiated by unique services (such as on-site dispensing of medication, medication monitoring, and integrated inpatient and outpatient oncology services), these pharmacies enable continuity of care.

Regional Insights

North America dominated the esophageal cancer market with a major revenue share in 2024. This is mainly due to its advanced healthcare infrastructure, established research oncology centers (e.g., MD Anderson Cancer Center and Johns Hopkins University), and high prevalence of esophageal cancer. The rising development of novel therapies, including immunotherapies, and the expansion of reimbursement policies for cancer treatments bolster the growth of the market.

Asia Pacific is emerging as the fastest-growing region in the market. There is a rising burden of squamous cell carcinoma in China, India, and Japan, creating the need for effective therapies. The rising healthcare expenditures and increase in clinical trials contribute to regional market growth.

Esophageal Cancer Market Coverage

Recent Development

• In March 2025, The FDA approved tislelizumab-jsgr (Tevimbra) plus platinum-containing chemotherapy for the frontline treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) with a tumor PD-L1 expression of 1 or higher.
  (Source: https://www.onclive.com)

Esophageal Cancer Market Key Players

• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• Novartis AG
• Amgen Inc.
• Johnson & Johnson (Janssen Biotech)
• Daiichi Sankyo Company, Limited
• GlaxoSmithKline plc (GSK)
• Bayer AG
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Illumina, Inc. (diagnostics)
• Thermo Fisher Scientific Inc. (diagnostics)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6348

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344